Clinical trials in Erlangen – page 17

390 clinical trials in Erlangen, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Erlangen at a glance

390

clinical trials

Research sites1

Quick filters

390 trials in Erlangen

Open in trial search

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

B precursor type acute leukaemia

Not yet recruiting

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Novartis Pharma AG

Contact Research Centre

Chronic kidney disease

Not yet recruiting

A study to evaluate the effect of survodutide on protein levels in the urine for patients with chronic kidney disease

Investigational

A study to evaluate the effect of survodutide on protein levels in the urine for patients with chronic kidney disease

Investigational

Germany

Participants:18–64 years · 65+ years
Substances:BI 456906
Sponsor:Universitair Medisch Centrum Groningen

Contact Research Centre

Hepatocellular carcinoma

Not yet recruiting

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo

A study to evaluate the safety and effectiveness of PF-08634404 and ipilimumab in adults with advanced or spreading liver cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Ipilimumab
Sponsor:Pfizer Inc.

Contact Research Centre

Systemic lupus erythematosus+1

Not yet recruiting

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo

Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:CC-97540
Sponsor:Celgene Corp.

Contact Research Centre

Colitis ulcerative

Not yet recruiting

Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis

InvestigationalNo placebo

Evaluating Treatment with Autologous Regulatory T-cells Given by Infusion in Adults with Ulcerative Colitis

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:AUTOLOGOUS REGULATORY T-CELLS WITH AN IMMUNOPHENOTYPE OF CD4+CD25HI/+FOXP3+
Sponsor:Universitaetsklinikum Erlangen AöR

Contact Research Centre

Fallopian tube cancer+1

Not yet recruiting

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Study of TORL-1-23 and pegfilgrastim in women with advanced platinum-resistant ovarian, peritoneal, or fallopian tube cancer expressing CLDN6

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Glatiramer Acetate
Sponsor:Torl Biotherapeutics LLC

Contact Research Centre

Medulloblastoma

Not yet recruiting

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Comparing two treatment regimens with drug combination for newly diagnosed low-risk medulloblastoma to evaluate cognitive function outcomes

Registered drugNo placebo

Germany

Participants:0–17 years
Substances:Carboplatin
Sponsor:GPOH gGmbH

Contact Research Centre

Polyomavirus-associated nephropathy

Not yet recruiting

Study on the Safety and Effectiveness of Tacrolimus and Drug Combination for Patients with BK Polyomavirus Infection After Kidney Transplantation

Registered drugNo placebo

Study on the Safety and Effectiveness of Tacrolimus and Drug Combination for Patients with BK Polyomavirus Infection After Kidney Transplantation

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Azathioprine

Contact Research Centre

Acute myeloid leukaemia

Not yet recruiting

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using CPX-351, Gemtuzumab Ozogamicin, and a Drug Combination

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years
Substances:Busulfan
Sponsor:GPOH gGmbH

Contact Research Centre

Malignant melanoma

Not yet recruiting

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo

Study Comparing MK-7684A (Vibostolimab and Pembrolizumab) with Pembrolizumab for Adults and Children with High-Risk Melanoma

Registered drugNo placebo

Germany

Participants:0–17 years · 18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Eli Lilly & Co.

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Erlangen

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on breast cancer treatments, including studies of new therapies for HR-positive and HER2-negative variants. Additional research encompasses lung cancer and various lymphomas.

Advanced/Metastatic Breast Cancer Treatments
Non-small Cell Lung Cancer Therapy
Lymphoma Treatment Approaches

Studies evaluate novel therapeutic combinations and targeted treatments for improved patient outcomes.

02 Autoimmune Conditions

Comprehensive research into various autoimmune disorders, including lupus erythematosus, psoriasis, and systemic conditions. Studies focus on innovative therapeutic approaches.

Cutaneous Lupus Treatment
Plaque Psoriasis Management
Systemic Sclerosis Research

Trials aim to develop more effective treatments for chronic autoimmune conditions.

03 Neurological Disorders

Clinical investigations focusing on acute cerebral ischemic stroke and multiple system atrophy. Research emphasizes innovative therapeutic approaches for better patient outcomes.

Stroke Treatment Development
Multiple System Atrophy Management
Neurological Disease Interventions

Studies evaluate new therapeutic agents and treatment strategies for neurological conditions.

Back to Germany All countries